tirzepatide percent weight loss generates 7% greater than #semaglutide in a real-world comparative effectiveness study. 42% tirzepatide pts lost >15% weight, compared to 19% of semaglutide. https://t.co/L9gyHVj0zs What is the expected weight

The extraordinary Mr Spitfire

SGLT2 Inhibitors and GLP-1 Agonists in Type 1 Diabetes: Off-Label Considerations While SGLT2 inhibitors and GLP-1 receptor agonists are not FDA-approved for type 1 diabetes in the US, their powerful cardiometabolic benefits have led to careful, off-label consideration in selected patients

Limited biased agonism (log (/K A )) was observed at the E354Q GIP receptor (Figure 2H) GIP(1-30)NH 2 appeared to be biased away from IP 1 (2-fold) and towards pCREB (7-fold) compared to cAMP accumulation, although these did not reach significance (Supplementary Table S2)

But some people, Oshman says, seem to feel certain medical conditions are okay to treat with drugs and others are not. Take, for instance, ADHD (short for attention deficit/hyperactivity disorder)